Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes
复制标题
DOI：
10.1002/cncr.10900
复制
发表时间：
2002-11-01
期刊：
影响因子：
6.2
通讯作者：
Albitar, M
中科院分区：
文献类型：
--
作者：
Aguayo, A;Kantarjian, HM;Albitar, M
背景血管内皮生长因子（VEGF）和碱性成纤维细胞生长因子（bFGF）是血管生成的正性调节因子。尿液、血清、血浆或恶性组织中的水平升高与实体瘤患者的不良预后相关。作者使用酶联免疫吸附测定法测定了99例既往未经治疗的骨髓增生异常综合征（MDS）（n = 41例; 42%）或急性髓性白血病（AML）（n = 58例; 58%）患者的血浆样本中VEGF和bFGF水平，并将结果与一组正常对照参与者的结果进行了比较。AML和MDS患者血浆中VEGF和bFGF的表达水平明显高于对照组（P < 0.01）。AML或MDS患者的VEGF血浆水平相似（中位数分别为30.63 pg/mL和34.41 pg/mL）。AML和MDS患者之间的bFGF水平无显著差异（中位数分别为6.38 pg/mL和6.98 pg/mL）。VEGF水平升高与AML患者生存率降低（P = 0.02）以及完全缓解（CR）率降低（P = 0.004）相关。在AML患者中，VEGF水平升高与缓解持续时间（CRD）缩短无关。MDS患者VEGF水平与生存率、CRD或CR率无相关性。bFGF水平与AML或MDS患者的CR率或生存率无相关性。血浆VEGF水平在AML患者中具有预后意义。MDS患者中VEGF水平缺乏临床相关性表明AML和MDS之间存在一些生物学差异。
BACKGROUND. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are positive regulators of angiogenesis. Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors.METHODS. The authors used an enzyme-linked immunosorbent assay to measure VEGF and bFGF levels in plasma samples from 99 patients with previously untreated myelodysplastic syndromes (MDS) (n = 41 patients; 42%) or acute myeloid leukemia (AML) (n = 58 patients; 58%) and compared the results with the results from a group of normal control participants.RESULTS. Increased expression levels of VEGF and bFGF were found in the plasma from patients with AML and MDS (P < 0.01) compared with the levels found in the control group. Plasma levels of VEGF in patients with AML or MDS were similar (median, 30.63 pg/mL and 34.41 pg/mL, respectively). There was no significant difference in bFGF levels between patients with AML and patients with MDS (median, 6.38 pg/mL and 6.98 pg/mL, respectively). Elevated levels of VEGF were associated with reduced survival (P = 0.02) in patients with AML as well as lower complete remission (CR) rates (P = 0.004). Elevated VEGF levels were not associated with reduced remission duration (CRD) in patients with AML. There was no correlation between VEGF levels and survival, CRD, or CR rates in patients with MDS. There was no correlation between bFGF levels and CR rates or survival in patients with either AML or MDS.CONCLUSIONS. Plasma VEGF levels have prognostic significance in patients with AML. The lack of clinical relevance of VEGF levels in patients with MDS suggests some biologic difference between AML and MDS.